RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA

J. P. Neijt, M. E L Van Der Burg, R. Vriesendorp, A. C M Van Lindert, M. Van Lent, W. W. Ten Bokkel Huinink, A. T Van Oosterom, C. D. Kooyman, J. V T H Hamerlynck, J. C Van Houwelingen, H. M. Pinedo

Research output: Contribution to journalArticlepeer-review

Abstract

186 patients with advanced epithelial ovarian carcinoma were treated with either a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) or cyclophosphamide and hexamethylmelamine alternating with doxorubicin and a 5-day course of cisplatin (CHAP-5). Treatment with CHAP-5 resulted in more complete remissions as determined by laparatomy or peritoneoscopy (p = 0·004), better overall response (p = 0·0001), and longer overall survival and progression-free survival (p

Original languageEnglish (US)
Pages (from-to)594-600
Number of pages7
JournalThe Lancet
Volume324
Issue number8403
DOIs
StatePublished - Sep 15 1984
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA'. Together they form a unique fingerprint.

Cite this